Contact this trialFirst, we need to learn more about you.
Vascular Endothelial Growth Factor (VEGF) Inhibitor
OPT-302 + Aflibercept for Age-Related Macular Degeneration
Recruiting1 awardPhase 3
Lake Worth, Florida
This trial will compare a new treatment to a sham (fake) treatment in order to see if the new treatment is effective. The primary efficacy will be determined at Week 52, meaning that's how long the trial will last.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service